Items Tagged ‘Advanced Stage Hodgkin’s Lymphoma’

June 20th, 2016

CAR Therapy Effective in Advanced Lymphoma

By

According to results of several presentations at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO), chimeric antigen receptor (CAR) therapies appear to have significant anti-cancer activity among patients with different types of lymphomas. This type of treatment is continuing to produce impressive results, and is demonstrating effectiveness in several different types […]

View full entry

Tags: Advanced Stage Hodgkin's Lymphoma, Aggressive/Intermediate Grade Non-Hodgkin's Lymphoma, asco, CAR, CAR T, chimeric antigen receptor, Follicular Lymphoma, Highly Aggressive/High Grade Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Leukemia, Lymphoma, Mantle Cell Non-Hodgkin's Lymphoma


December 23rd, 2014

Keytruda PD-1 Immunotherapy Shows Promise in Hodgkin’s Lymphoma

By

The cancer immunotherapy strategy known as programmed cell death 1 (PD-1) has generated great excitement for its ability to help the immune system recognize and attack cancer. Now according to researchers at the American Society of Hematology (ASH) 56th Annual Meeting, PD-1 blockade has demonstrated efficacy in patients with Hodgkin lymphoma (HL). Hodgkin’s lymphoma is […]

View full entry

Tags: Advanced Stage Hodgkin's Lymphoma, HD, hodgkin's disease, Hodgkin's Lymphoma, keytruda, Lymphoma, News, pembrolizumab, Progressive Relapsed Hodgkin's Lymphoma


December 18th, 2014

PD-1 Immunotherapy Shows Promise in Hodgkin’s Lymphoma

By

The cancer immunotherapy strategy known as programmed cell death 1 (PD-1) has generated great excitement for its ability to help the immune system recognize and attack cancer. Now according to researcher recently published in The New England Journal of Medicine, PD-1 blockade has demonstrated effectiveness in patients with Hodgkin lymphoma (HL). Hodgkin’s lymphoma is a […]

View full entry

Tags: Advanced Stage Hodgkin's Lymphoma, HD, HL, Hodgkin's Lymphoma, Lymphoma, News, nivolumab, PD-1, Progressive Relapsed Hodgkin's Lymphoma


December 12th, 2014

Post-Transplant Adcetris® Improves Treatment of Hodgkin’s Lymphoma and is Likely to Become New Standard of Care

By

The use of post stem cell transplant (SCT) maintenance therapy with Adcetris® (brentuximab vedotin) significantly improved progression-free survival in Hodgkin’s Lymphoma (HL) according to the results of a clinical trail presented at the 56th American Hematological Society Annual Meeting and Exposition, December 6–9, 2014, in San Francisco, California. Hodgkin’s lymphoma is a cancer of the […]

View full entry

Tags: adcetris, Advanced Stage Hodgkin's Lymphoma, Early Stage Hodgkin's Lymphoma, HL, hodgkin lymphoma, Hodgkin's Lymphoma, News, sct


February 26th, 2014

Rituxan Active in Nodular Lymphocyte-Predominant Hodgkin’s Lymphoma

By

Rituxan® (rituximab) was active in previously treated and untreated patients with nodular lymphocyte–predominant Hodgkin lymphoma, according to the results of a phase II study published in the Journal of Clinical Oncology. Most patients relapsed, but durable response was observed in a substantial minority. Hodgkin’s lymphoma is a cancer of the lymph system and typically begins in […]

View full entry

Tags: Advanced Stage Hodgkin's Lymphoma, Early Stage Hodgkin's Lymphoma, Hodgkin's Lymphoma, News


January 16th, 2014

Adcetris and PET-Adapted Salvage Therapy Effective in Relapsed/Refractory Hodgkin’s Lymphoma

By

Patients with relapsed/refractory Hodgkin’s lymphoma who achieve complete responses after treatment with Adcetris® (brentuximab vedotin) can skip more toxic salvage therapy and proceed straight to transplant, according to the results of a study presented at the 2013 International Symposium on Hodgkin Lymphoma in Cologne, Germany. Hodgkin’s lymphoma is a cancer of the lymph system. It […]

View full entry

Tags: Advanced Stage Hodgkin's Lymphoma, Hodgkin's Lymphoma, News, Progressive Relapsed Hodgkin's Lymphoma


January 14th, 2014

Adcetris Improves Response Rates to ABVD in Hodgkin’s Lymphoma

By

Adding Adcetris® (brentuximab vedotin) to the chemotherapy regimen ABVD produces a high complete response rate with a moderate increase in toxicity in patients with advanced Hodgkin’s lymphoma, according to the results of a study presented at the 19th International Symposium on Hodgkin Lymphoma held in Cologne, Germany in 2014. Hodgkin’s lymphoma is a cancer of […]

View full entry

Tags: Advanced Stage Hodgkin's Lymphoma, Hodgkin's Lymphoma, News, Progressive Relapsed Hodgkin's Lymphoma


March 14th, 2012

Lymphoma During Pregnancy Can Have Good Outcomes

By

Among women who are diagnosed with lymphoma during pregnancy, the outcomes for both mother and baby are often good. This was true for women who began lymphoma treatment during the second or third trimester of pregnancy, as well as women who deferred treatment until after delivery. These results were presented at the 2011 annual meeting […]

View full entry

Tags: Advanced Stage Hodgkin's Lymphoma, Aggressive/Intermediate Grade Non-Hodgkin's Lymphoma, Early Stage Hodgkin's Lymphoma, Follicular Lymphoma, Highly Aggressive/High Grade Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Indolent/Low Grade Non-Hodgkin's Lymphoma, Mantle Cell Non-Hodgkin's Lymphoma, News, Non-Hodgkin's Lymphoma, T-Cell Non-Hodgkin's Lymphoma


July 25th, 2011

Similar Overall Survival with ABVD and BEACOPP for Advanced Hodgkin’s Lymphoma

By

Although the BEACOPP chemotherapy regimen produces better initial tumor control than the commonly used and less toxic ABVD regimen, the two regimens produce similar overall survival among patients with advanced Hodgkin’s lymphoma. These results were published in the New England Journal of Medicine. Hodgkin’s lymphoma is a cancer of the lymph system. It is diagnosed […]

View full entry

Tags: Advanced Stage Hodgkin's Lymphoma, Hodgkin's Lymphoma, News


May 23rd, 2011

Many Patients with “Chemo Brain” Recover within Five Years

By

A study of “chemo brain”—the foggy thinking and forgetfulness that patients may experience after chemotherapy—suggests that the condition improves substantially over time for a majority of patients. For some patients, however, symptoms may persist for more than five years after treatment. These findings were recently reported in the Journal of Clinical Oncology. Chemo brain refers […]

View full entry

Tags: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Promyelocytic Leukemia, Adult Acute Lymphoblastic Leukemia, Advanced Stage Hodgkin's Lymphoma, Aggressive/Intermediate Grade Non-Hodgkin's Lymphoma, Allogeneic Stem Cell Transplant, Childhood Acute Lymphoblastic Leukemia, Chronic Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Early Stage Hodgkin's Lymphoma


February 5th, 2009

Hodgkin's Survivors: Increased Fatigue, Cardiac, and Thyroid Complications

By

According to an article published in the Annals of Oncology, survivors of Hodgkin’s lymphoma have a significantly increased rate of cardiac and thyroid complications than their siblings. In addition, survivors tend to have more fatigue than their siblings; however, this may in part be associated with cardiac issues. Researchers from the Brigham and Women’s Hospital […]

View full entry

Tags: Advanced Stage Hodgkin's Lymphoma, Early Stage Hodgkin's Lymphoma, Hodgkin's Lymphoma, Progressive Relapsed Hodgkin's Lymphoma


September 29th, 2008

Survival Rates Improving in Childhood Hematologic Cancers

By

Survival Rates Improving in Childhood Hematologic Cancers Five- and 10-year survival rates in childhood hematalogic cancers have significantly improved since 1990, according to the results of a study recently published in the Journal of the National Cancer Institute. Approximately 40% of childhood cancers are classified as hematalogic cancers. Hematologic cancers are cancers of the blood […]

View full entry

Tags: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Advanced Stage Hodgkin's Lymphoma, Aggressive/Intermediate Grade Non-Hodgkin's Lymphoma, Early Stage Hodgkin's Lymphoma, Highly Aggressive/High Grade Non-Hodgkin's Lymphoma, Indolent/Low Grade Non-Hodgkin's Lymphoma